HELSINKI, 12 March 2026 - Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...
4d
A vitamin cocktail, straight to the vein. IV drip bars boom in Boston, but are they worth the hype?
Myers’ Cocktail: Perhaps the best-known IV blend, this mixture of vitamin C, B vitamins, magnesium, and calcium dates back to ...
Solutions Market size was USD 3.91 Billion in 2025 and is expected to reach USD 8.39 Billion by 2035 owing to advanced healthcare infrastructure globallyAustin, March 13, 2026 (GLOBE NEWSWIRE) -- ...
Diablo Immortal’s Patch 4.3 The Taking adds a new story arc, Rocky Waste subzone, PvP overhaul, equalized tournament, and a ...
Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...
FUJIFILM Sonosite, Inc., a global leader in point-of-care ultrasound (POCUS) solutions, announces the launch of PIV Assist, a new AI-powered feature designed to assist clinicians in planning ...
It’s a common practice — maintaining peripheral intravenous catheters (PIVCs) in stable hospital patients even after the need for IV therapy has been resolved. And the thinking goes, why not? After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results